Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 8/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680407 | 0.84 | ESR1 (0.49) | ESR1PPARDKMT2AMEN1KDM4E | |
| Trifluoroacetic Acid SCHEMBL3694964 | 0.80 | ESR1 (0.46) | ESR1PPARDPPARA | |
| SCHEMBL3587513 | 0.78 | ESR1 (0.48) | ESR1PPARDPPARAKMT2AMEN1 | |
| SCHEMBL3680656 | 0.76 | ESR1 (0.49) | ESR1PPARDKMT2AMEN1KDM4E | |
| SCHEMBL3683445 | 0.75 | ESR1 (0.48) | ESR1PPARDKMT2AMEN1KDM4E | |
| SCHEMBL13442122 | 0.75 | ESR1 (0.48) | ESR1PPARDPPARAKMT2AMEN1 | |
| SCHEMBL3687182 | 0.75 | ESR1 (0.45) | ESR1PPARDPPARAKMT2AMEN1 | |
| SCHEMBL3681632 | 0.75 | ESR1 (0.50) | ESR1PPARDKMT2AMEN1KDM4E | |
| SCHEMBL3583564 | 0.75 | ESR1 (0.50) | ESR1PPARDPPARAKMT2AMEN1 | |
| SCHEMBL5182260 | 0.75 | MAPK1 (0.42) | ESR1KMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | ESR1 1864/4885LTA4H 2622/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.